Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Phys Sportsmed. 2010 Apr;38(1):11-20. doi: 10.3810/psm.2010.04.1757.
Hypertension is a prevalent disease worldwide. Its inadequate treatment leads to major cardiovascular complications, such as myocardial infarction, stroke, and heart failure. These conditions decrease life expectancy and are a substantial cost burden to health care systems. Physically active individuals and professional athletes are not risk free for developing this condition. Although the percentage of persons affected is substantially lower than the general population, these individuals still need to be thoroughly evaluated and blood pressure targets monitored to allow safe competitive sports participation. Regarding treatment, lifestyle modification measures should be routinely emphasized to athletes and active individuals with the same importance as for the general population. Medication treatment can be complicated because of restrictions by athletic organizations and possible limitations on maximal exercise performance. In addition, the choice of an antihypertensive drug should be made with consideration for salt and water losses that routinely occur in athletes, as well as preservation of exercise performance and endothelial function. First-line therapies for athletes and physically active individuals may be different from the general population. Some authorities believe that blocking the renin-angiotensin system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is more beneficial compared with diuretics because of ACE inhibitors and ARBs being able to avoid salt and water losses. Dihydropyridine calcium channel blockers (CCBs) are another reasonable choice. Despite effects on heart rate, nondihydropyridine CCBs do not appear to impair exercise performance. beta-Blockers are not used as a first-line therapy in athletes because of effects on exercise and prohibition by the National Collegiate Athletic Association and World Anti-Doping Agency in certain sports. In this article, we address the evidence on hypertension and its related treatments in active individuals to provide recommendations that allow the best competitive sports results and reduce cardiovascular risk.
高血压是一种全球性的常见病。其治疗不充分会导致主要的心血管并发症,如心肌梗死、中风和心力衰竭。这些情况会降低预期寿命,并给医疗保健系统带来巨大的经济负担。身体活跃的个人和职业运动员并非完全没有患上这种疾病的风险。尽管受影响的人数比例明显低于一般人群,但这些人仍需要进行彻底评估,并监测血压目标,以允许安全地参加竞技体育。关于治疗,应像对一般人群一样,向运动员和活跃个体强调生活方式改变措施的重要性。由于体育组织的限制和对最大运动表现的可能限制,药物治疗可能会变得复杂。此外,应考虑运动员经常出现的盐和水丢失以及运动表现和内皮功能的保留,来选择抗高血压药物。运动员和活跃个体的一线治疗方法可能与一般人群不同。一些权威人士认为,与利尿剂相比,用血管紧张素转换酶 (ACE) 抑制剂或血管紧张素受体阻滞剂 (ARB) 阻断肾素-血管紧张素系统更为有益,因为 ACE 抑制剂和 ARB 能够避免盐和水丢失。二氢吡啶钙通道阻滞剂 (CCB) 也是另一种合理的选择。尽管对心率有影响,但非二氢吡啶 CCB 似乎不会损害运动表现。β-受体阻滞剂由于对运动的影响以及美国全国大学体育协会和世界反兴奋剂机构在某些运动中对其的禁止,不被用作运动员的一线治疗药物。在本文中,我们将探讨有关活跃个体中高血压及其相关治疗的证据,以提供允许最佳竞技体育成绩和降低心血管风险的建议。